Financhill
Sell
38

ALKS Quote, Financials, Valuation and Earnings

Last price:
$29.22
Seasonality move :
4.02%
Day range:
$29.09 - $29.60
52-week range:
$24.48 - $36.45
Dividend yield:
0%
P/E ratio:
13.98x
P/S ratio:
3.25x
P/B ratio:
3.19x
Volume:
1.4M
Avg. volume:
1.7M
1-year change:
18.54%
Market cap:
$4.8B
Revenue:
$1.6B
EPS (TTM):
$2.09

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ALKS
Alkermes PLC
$341.4M $0.38 -14.01% -21.1% $41.19
AMRN
Amarin Corp PLC
$53.4M -$0.61 -20.31% -- $10.50
AVDL
Avadel Pharmaceuticals PLC
$61.4M $0.03 48.09% -76.67% $17.25
JAZZ
Jazz Pharmaceuticals PLC
$1B -$6.26 4.15% 45.93% $185.73
MDT
Medtronic PLC
$8.8B $1.58 5.7% 53.51% $97.21
PRGO
Perrigo Co PLC
$1.1B $0.59 1.58% 5557.8% $36.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ALKS
Alkermes PLC
$29.22 $41.19 $4.8B 13.98x $0.00 0% 3.25x
AMRN
Amarin Corp PLC
$15.82 $10.50 $327.6M -- $0.00 0% 1.53x
AVDL
Avadel Pharmaceuticals PLC
$10.83 $17.25 $1B -- $0.00 0% 5.36x
JAZZ
Jazz Pharmaceuticals PLC
$112.87 $185.73 $6.8B 15.05x $0.00 0% 1.77x
MDT
Medtronic PLC
$89.61 $97.21 $114.8B 24.75x $0.71 3.14% 3.45x
PRGO
Perrigo Co PLC
$26.96 $36.50 $3.7B -- $0.29 4.2% 0.86x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ALKS
Alkermes PLC
-- 0.948 -- 2.72x
AMRN
Amarin Corp PLC
-- 1.987 -- 2.39x
AVDL
Avadel Pharmaceuticals PLC
-- -1.622 -- 2.12x
JAZZ
Jazz Pharmaceuticals PLC
56.25% 0.495 70.16% 2.64x
MDT
Medtronic PLC
37.21% 0.556 26.13% 1.20x
PRGO
Perrigo Co PLC
45.39% 0.740 94.29% 1.05x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ALKS
Alkermes PLC
$257.3M $13.8M 22.98% 25.91% 8.32% $88.7M
AMRN
Amarin Corp PLC
$25.1M -$16.8M -16.98% -16.98% -39.88% -$12.5M
AVDL
Avadel Pharmaceuticals PLC
$46.9M -$3M -35.57% -35.57% -4.96% -$8.2M
JAZZ
Jazz Pharmaceuticals PLC
$793.2M -$55.9M 4.93% 12.12% -6.25% $390.9M
MDT
Medtronic PLC
$5.8B $1.8B 6.11% 9.51% 16.08% $2.1B
PRGO
Perrigo Co PLC
$392.3M $79.4M -2.12% -4.01% 4.53% -$90M

Alkermes PLC vs. Competitors

  • Which has Higher Returns ALKS or AMRN?

    Amarin Corp PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -37.36%. Alkermes PLC's return on equity of 25.91% beat Amarin Corp PLC's return on equity of -16.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALKS
    Alkermes PLC
    83.95% $0.13 $1.5B
    AMRN
    Amarin Corp PLC
    59.81% -$0.80 $473.7M
  • What do Analysts Say About ALKS or AMRN?

    Alkermes PLC has a consensus price target of $41.19, signalling upside risk potential of 40.96%. On the other hand Amarin Corp PLC has an analysts' consensus of $10.50 which suggests that it could fall by -33.63%. Given that Alkermes PLC has higher upside potential than Amarin Corp PLC, analysts believe Alkermes PLC is more attractive than Amarin Corp PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALKS
    Alkermes PLC
    10 5 0
    AMRN
    Amarin Corp PLC
    0 1 1
  • Is ALKS or AMRN More Risky?

    Alkermes PLC has a beta of 0.407, which suggesting that the stock is 59.265% less volatile than S&P 500. In comparison Amarin Corp PLC has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.66%.

  • Which is a Better Dividend Stock ALKS or AMRN?

    Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Amarin Corp PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALKS or AMRN?

    Alkermes PLC quarterly revenues are $306.5M, which are larger than Amarin Corp PLC quarterly revenues of $42M. Alkermes PLC's net income of $22.5M is higher than Amarin Corp PLC's net income of -$15.7M. Notably, Alkermes PLC's price-to-earnings ratio is 13.98x while Amarin Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.25x versus 1.53x for Amarin Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALKS
    Alkermes PLC
    3.25x 13.98x $306.5M $22.5M
    AMRN
    Amarin Corp PLC
    1.53x -- $42M -$15.7M
  • Which has Higher Returns ALKS or AVDL?

    Avadel Pharmaceuticals PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -9.37%. Alkermes PLC's return on equity of 25.91% beat Avadel Pharmaceuticals PLC's return on equity of -35.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALKS
    Alkermes PLC
    83.95% $0.13 $1.5B
    AVDL
    Avadel Pharmaceuticals PLC
    89.38% -$0.05 $74.1M
  • What do Analysts Say About ALKS or AVDL?

    Alkermes PLC has a consensus price target of $41.19, signalling upside risk potential of 40.96%. On the other hand Avadel Pharmaceuticals PLC has an analysts' consensus of $17.25 which suggests that it could grow by 59.28%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Alkermes PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALKS
    Alkermes PLC
    10 5 0
    AVDL
    Avadel Pharmaceuticals PLC
    5 0 0
  • Is ALKS or AVDL More Risky?

    Alkermes PLC has a beta of 0.407, which suggesting that the stock is 59.265% less volatile than S&P 500. In comparison Avadel Pharmaceuticals PLC has a beta of 1.419, suggesting its more volatile than the S&P 500 by 41.933%.

  • Which is a Better Dividend Stock ALKS or AVDL?

    Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Avadel Pharmaceuticals PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALKS or AVDL?

    Alkermes PLC quarterly revenues are $306.5M, which are larger than Avadel Pharmaceuticals PLC quarterly revenues of $52.5M. Alkermes PLC's net income of $22.5M is higher than Avadel Pharmaceuticals PLC's net income of -$4.9M. Notably, Alkermes PLC's price-to-earnings ratio is 13.98x while Avadel Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.25x versus 5.36x for Avadel Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALKS
    Alkermes PLC
    3.25x 13.98x $306.5M $22.5M
    AVDL
    Avadel Pharmaceuticals PLC
    5.36x -- $52.5M -$4.9M
  • Which has Higher Returns ALKS or JAZZ?

    Jazz Pharmaceuticals PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -10.31%. Alkermes PLC's return on equity of 25.91% beat Jazz Pharmaceuticals PLC's return on equity of 12.12%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALKS
    Alkermes PLC
    83.95% $0.13 $1.5B
    JAZZ
    Jazz Pharmaceuticals PLC
    88.35% -$1.52 $9.5B
  • What do Analysts Say About ALKS or JAZZ?

    Alkermes PLC has a consensus price target of $41.19, signalling upside risk potential of 40.96%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $185.73 which suggests that it could grow by 64.56%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Alkermes PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALKS
    Alkermes PLC
    10 5 0
    JAZZ
    Jazz Pharmaceuticals PLC
    13 1 0
  • Is ALKS or JAZZ More Risky?

    Alkermes PLC has a beta of 0.407, which suggesting that the stock is 59.265% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.321, suggesting its less volatile than the S&P 500 by 67.888%.

  • Which is a Better Dividend Stock ALKS or JAZZ?

    Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALKS or JAZZ?

    Alkermes PLC quarterly revenues are $306.5M, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $897.8M. Alkermes PLC's net income of $22.5M is higher than Jazz Pharmaceuticals PLC's net income of -$92.5M. Notably, Alkermes PLC's price-to-earnings ratio is 13.98x while Jazz Pharmaceuticals PLC's PE ratio is 15.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.25x versus 1.77x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALKS
    Alkermes PLC
    3.25x 13.98x $306.5M $22.5M
    JAZZ
    Jazz Pharmaceuticals PLC
    1.77x 15.05x $897.8M -$92.5M
  • Which has Higher Returns ALKS or MDT?

    Medtronic PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of 11.83%. Alkermes PLC's return on equity of 25.91% beat Medtronic PLC's return on equity of 9.51%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALKS
    Alkermes PLC
    83.95% $0.13 $1.5B
    MDT
    Medtronic PLC
    64.75% $0.82 $76.7B
  • What do Analysts Say About ALKS or MDT?

    Alkermes PLC has a consensus price target of $41.19, signalling upside risk potential of 40.96%. On the other hand Medtronic PLC has an analysts' consensus of $97.21 which suggests that it could grow by 8.48%. Given that Alkermes PLC has higher upside potential than Medtronic PLC, analysts believe Alkermes PLC is more attractive than Medtronic PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALKS
    Alkermes PLC
    10 5 0
    MDT
    Medtronic PLC
    13 13 0
  • Is ALKS or MDT More Risky?

    Alkermes PLC has a beta of 0.407, which suggesting that the stock is 59.265% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.64%.

  • Which is a Better Dividend Stock ALKS or MDT?

    Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.14% to investors and pays a quarterly dividend of $0.71 per share. Alkermes PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 76.98% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ALKS or MDT?

    Alkermes PLC quarterly revenues are $306.5M, which are smaller than Medtronic PLC quarterly revenues of $8.9B. Alkermes PLC's net income of $22.5M is lower than Medtronic PLC's net income of $1.1B. Notably, Alkermes PLC's price-to-earnings ratio is 13.98x while Medtronic PLC's PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.25x versus 3.45x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALKS
    Alkermes PLC
    3.25x 13.98x $306.5M $22.5M
    MDT
    Medtronic PLC
    3.45x 24.75x $8.9B $1.1B
  • Which has Higher Returns ALKS or PRGO?

    Perrigo Co PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -0.61%. Alkermes PLC's return on equity of 25.91% beat Perrigo Co PLC's return on equity of -4.01%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALKS
    Alkermes PLC
    83.95% $0.13 $1.5B
    PRGO
    Perrigo Co PLC
    37.58% -$0.05 $8B
  • What do Analysts Say About ALKS or PRGO?

    Alkermes PLC has a consensus price target of $41.19, signalling upside risk potential of 40.96%. On the other hand Perrigo Co PLC has an analysts' consensus of $36.50 which suggests that it could grow by 35.39%. Given that Alkermes PLC has higher upside potential than Perrigo Co PLC, analysts believe Alkermes PLC is more attractive than Perrigo Co PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALKS
    Alkermes PLC
    10 5 0
    PRGO
    Perrigo Co PLC
    1 2 0
  • Is ALKS or PRGO More Risky?

    Alkermes PLC has a beta of 0.407, which suggesting that the stock is 59.265% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.881%.

  • Which is a Better Dividend Stock ALKS or PRGO?

    Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.2% to investors and pays a quarterly dividend of $0.29 per share. Alkermes PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend.

  • Which has Better Financial Ratios ALKS or PRGO?

    Alkermes PLC quarterly revenues are $306.5M, which are smaller than Perrigo Co PLC quarterly revenues of $1B. Alkermes PLC's net income of $22.5M is higher than Perrigo Co PLC's net income of -$6.4M. Notably, Alkermes PLC's price-to-earnings ratio is 13.98x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.25x versus 0.86x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALKS
    Alkermes PLC
    3.25x 13.98x $306.5M $22.5M
    PRGO
    Perrigo Co PLC
    0.86x -- $1B -$6.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Bloom Energy Flying Under the Radar?
Is Bloom Energy Flying Under the Radar?

Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 59x

Buy
61
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
55
TLN alert for Jul 19

Talen Energy [TLN] is up 24.44% over the past day.

Sell
48
CRSP alert for Jul 19

CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.

Buy
83
SOC alert for Jul 19

Sable Offshore [SOC] is up 11.86% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock